» Articles » PMID: 25357074

The Significance of Mycobacterium Abscessus Subspecies Abscessus Isolation During Mycobacterium Avium Complex Lung Disease Therapy

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2014 Oct 31
PMID 25357074
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Isolation of Mycobacterium abscessus subspecies abscessus (MAA) is common during Mycobacterium avium complex (MAC) lung disease therapy, but there is limited information about the clinical significance of the MAA isolates.

Methods: We identified 53 of 180 patients (29%) treated for MAC lung disease who had isolation of MAA during MAC lung disease therapy. Patients were divided into those without (group 1) and those with (group 2) MAA lung disease.

Results: There were no significant demographic differences between patients with and without MAA isolation or between groups 1 and 2. Group 1 and 2 patients had similar total sputum cultures obtained (P = .7; 95% CI, -13.4 to 8.6) and length of follow-up (P = .8; 95% CI, -21.5 to 16.1). Group 2 patients had significantly more total positive cultures for MAA (mean±SD, 15.0 ± 11.1 vs 1.2 ± 0.4; P < .0001; 95% CI, -17.7 to -9.9), were significantly more likely to develop new or enlarging cavitary lesions while on MAC therapy (P > .0001), and were significantly more likely to meet all three American Thoracic Society diagnostic criteria for nontuberculous mycobacterial disease (21 of 21 [100%] vs 0 of 32 [0%]; P < .0001) compared with group 1 patients. Group 1 patients were significantly more likely to have single, positive MAA cultures than group 2 patients (25 of 31 vs 0 of 21; P < .0001).

Conclusions: Microbiologic and clinical follow-up after completion of MAC lung disease therapy is required to determine the significance of MAA isolated during MAC lung disease therapy. Single MAA isolates are not likely to be clinically significant.

Citing Articles

Mixed infection of three nontuberculous mycobacteria species identified by metagenomic next-generation sequencing in a patient with peritoneal dialysis-associated peritonitis: a rare case report and literature review.

Chen X, Zhu J, Liu Z, Ye J, Yang L, Zhang Z BMC Nephrol. 2023; 24(1):95.

PMID: 37055720 PMC: 10099677. DOI: 10.1186/s12882-023-03156-8.


Identification and Characteristics of Co-isolation of Multiple Nontuberculous Mycobacteria.

Asaoka M, Hagiwara E, Etori S, Higa K, Ikeda S, Sekine A Intern Med. 2021; 60(20):3213-3219.

PMID: 33896860 PMC: 8580763. DOI: 10.2169/internalmedicine.5300-20.


Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease.

Fujiwara K, Furuuchi K, Aono A, Uesugi F, Shirai T, Nakamoto K Eur J Clin Microbiol Infect Dis. 2020; 40(2):247-254.

PMID: 32875518 DOI: 10.1007/s10096-020-04026-z.


Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C Eur Respir J. 2020; 56(1).

PMID: 32636299 PMC: 8375621. DOI: 10.1183/13993003.00535-2020.


Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C Clin Infect Dis. 2020; 71(4):e1-e36.

PMID: 32628747 PMC: 7768748. DOI: 10.1093/cid/ciaa241.


References
1.
Wallace Jr R, Brown B, Griffith D, Girard W, Murphy D, Onyi G . Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994; 149(5):1335-41. DOI: 10.1164/ajrccm.149.5.8173775. View

2.
Wallace Jr R, Brown B, Griffith D, Girard W, Murphy D . Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996; 153(6 Pt 1):1766-72. DOI: 10.1164/ajrccm.153.6.8665032. View

3.
Cheng A, Liu Y, Chen M, Hung C, Tsai Y, Sheng W . Extrapulmonary infections caused by a dominant strain of Mycobacterium massiliense (Mycobacterium abscessus subspecies bolletii). Clin Microbiol Infect. 2013; 19(10):E473-82. DOI: 10.1111/1469-0691.12261. View

4.
Jun H, Jeon K, Um S, Kwon O, Lee N, Koh W . Nontuberculous mycobacteria isolated during the treatment of pulmonary tuberculosis. Respir Med. 2009; 103(12):1936-40. DOI: 10.1016/j.rmed.2009.05.025. View

5.
Griffith D, Girard W, Wallace Jr R . Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. 1993; 147(5):1271-8. DOI: 10.1164/ajrccm/147.5.1271. View